Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene tests today.

19 December 2016 Price $7.20 1yr Target $10.25 Analysts --- Dividend $--- Payout Ratio --- 1yr Cap Gain 42.36% Yield --- 1yr Tot Return 42.36% P/E --- PEG --- Beta --- | EPS (ttm) $-3.11 EPS next yr $-2.43 Forward P/E --- EPS next 5yr 8.00% 1yr Price Support $--- Market Cap $282.10 Mil Revenues $19.00 Mil Earnings $-99.80 Mil Profit Margin --- Quick Ratio 5.60 Current Ratio 5.60 Debt/Equity 0.21 | 1yr RevGR --- 3yr RevGR --- 5yr RevGR --- 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -77.00% ROE -95.80% |
My Opinion
Based upon an inspection of the fundamentals as well as the technicals, I can't find any basis in the type of investing I do that would justify buying any shares of this company. But there's something about this whole area of science that's intriging. And I want to be part of that excitement.
So I can't justify owning shares in this company by any stretch of the imagination but contrary to my own advice, I intend to start a position in this company in the very near future. If I live long enough I may live to regret this decision but it won't be the first time I did something dumb in the market and lost money. And it probably won't be my last time either.